Immunic tests Nurr1 to push beyond MS’s inflammation ceiling 

BTK inhibitors have become the most advanced test of whether multiple sclerosis therapies can move beyond relapse control to slow disability progression, but mixed regulatory, safety, and efficacy signals leave room for alternative approaches. Immunic Inc.’s vidofludimus calcium is one such test case, pairing DHODH inhibition with Nurr1 activation in an attempt to combine targeted immune modulation with direct neuroprotective effects.

Outside the BTK class, the field has few advanced clinical examples of therapies designed to pair immune modulation with direct effects on neurodegeneration, repair, or CNS resilience. Setbacks in remyelination have underscored how hard neuroprotective and repair hypotheses are to translate, making vidofludimus a useful test of whether adding a CNS-directed mechanism to a validated anti-inflammatory target class can produce effects on progression...